High-risk retinoblastoma based on age at primary enucleation: a study of 616 eyes.
Journal
Eye (London, England)
ISSN: 1476-5454
Titre abrégé: Eye (Lond)
Pays: England
ID NLM: 8703986
Informations de publication
Date de publication:
08 2020
08 2020
Historique:
received:
11
06
2019
accepted:
03
10
2019
revised:
17
09
2019
pubmed:
27
11
2019
medline:
22
6
2021
entrez:
27
11
2019
Statut:
ppublish
Résumé
To study the high-risk histopathology features of retinoblastoma based on age at primary enucleation. Retrospective study of 616 patients. The mean age at presentation and primary enucleation for retinoblastoma was 34 months (median, 28 months; range, <1-455 months). Of these cases, 128 (21%) were aged ≤1 year, 149 (24%) were in the age group of 1-2 years, 117 (19%) in 2-3 years, 104 (17%) in 3-4 years, and 118 (19%) were >4 years of age at the time of enucleation. Bilateral retinoblastoma (34%; p < 0.0001) and buphthalmos (20%; p < 0.0001) were more common in children ≤1 year of age. Anterior chamber pseudohypopyon (15%; p < 0.0001) and vitreous seeds (53%; p < 0.0001) were more common in children aged >4 years. Based on 8th edition American Joint Committee on Cancer staging system, pT3 was less common in children ≤1 year of age (13%; p < 0.001). Based on histopathology, 38% patients had high-risk features including 24% children aged ≤1 year, 42% in the age group of 1-2 years, 34% in 2-3 years age group, 45% in 3-4 years age group, and 48% patients were >4 years of age. Post-laminar optic nerve infiltration (6%; p = 0.02) and massive choroidal infiltration (9%; p = 0.04) was least common in children ≤1 year of age. Over a mean follow-up period of 52 months (median, 36 months; range, <1-218 months), systemic metastasis and death occurred in 9% patients despite adjuvant systemic chemotherapy. The predominant high-risk histopathology feature of retinoblastoma varies with age at primary enucleation.
Identifiants
pubmed: 31767966
doi: 10.1038/s41433-019-0698-2
pii: 10.1038/s41433-019-0698-2
pmc: PMC7376026
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1441-1448Références
Kaliki S, Patel A, Iram S, Ramappa G, Mohamed A, Palkonda VAR. Retinoblastoma in India: clinical presentation and outcome in 1457 Patients (2074 Eyes). Retina. 2019;39:379–91.
doi: 10.1097/IAE.0000000000001962
Fabian ID, Stacey AW, Chowdhury T, Duncan C, Karaa EK, Scheimberg I, et al. High-risk histopathology features in primary and secondary enucleated international intraocular retinoblastoma classification group D eyes. Ophthalmology. 2017;124:851–8.
doi: 10.1016/j.ophtha.2017.01.048
Kaliki S, Shields CL, Shah SU, Eagle RC Jr, Shields JA, Leahey A. Postenucleation adjuvant chemotherapy with vincristine, etoposide, and carboplatin for the treatment of high-risk retinoblastoma. Arch Ophthalmol. 2011;129:1422–7.
doi: 10.1001/archophthalmol.2011.289
Kaliki S, Srinivasan V, Gupta A, Mishra DK, Naik MN. Clinical features predictive of high-risk retinoblastoma in 403 Asian Indian patients: a case-control study. Ophthalmology. 2015;122:1165–72.
doi: 10.1016/j.ophtha.2015.01.018
Sreelakshmi KV, Chandra A, Krishnakumar S, Natarajan V, Khetan V. Anterior chamber invasion in retinoblastoma: not an indication for adjuvant chemotherapy. Invest Ophthalmol Vis Sci. 2017;58:4654–61.
doi: 10.1167/iovs.17-22111
Chantada GL, Dunkel IJ, de Dávila MT, Abramson DH. Retinoblastoma patients with high risk ocular pathological features: who needs adjuvant therapy? Br J Ophthalmol. 2004;88:1069–73.
doi: 10.1136/bjo.2003.037044
Kaliki S, Shields CL, Eagle RC Jr, Iram S, Shields JA. High-risk intraocular retinoblastoma: comparison between Asian Indians and Americans from two major referral centers. Retina. 2018;38:2023–9.
doi: 10.1097/IAE.0000000000001816
Kivelä TT, Hadjistilianou T. Neonatal retinoblastoma. Asia Pac J Oncol Nurs. 2017;4:197–204.
doi: 10.4103/apjon.apjon_18_17
Abramson DH, Du TT, Beaverson KL. (Neonatal) retinoblastoma in the first month of life. Arch Ophthalmol. 2002;120:738–42.
doi: 10.1001/archopht.120.6.738
Abramson DH, Notterman RB, Ellsworth RM, Kitchin FD. Retinoblastoma treated in infants in the first six months of life. Arch Ophthalmol. 1983;101:1362–6.
doi: 10.1001/archopht.1983.01040020364004
Shields CL, Shields JA, Shah P. Retinoblastoma in older children. Ophthalmology 1991;98:395–9.
doi: 10.1016/S0161-6420(91)32283-8
Reese AB, Ellsworth RM. The evaluation and current concept of retinoblastoma therapy. Trans Am Acad Ophthalmol Otolaryngol. 1963;67:164–72.
pubmed: 13973597
Shields CL, Mashayekhi A, Au AK, Czyz C, Leahey A, Meadows AT, et al. The International Classification of Retinoblastoma predicts chemoreduction success. Ophthalmology. 2006;113:2276–80.
doi: 10.1016/j.ophtha.2006.06.018
Mallipatna AC, Gallie BL, Chévez-Barrios P, Lumbroso-Le Rouic L, Chantada G, et al. Retinoblastoma. In: Amin MB, Edge SB, Greene FL, Byrd DR, Brookland RK, et al., editors. AJCC Cancer Staging Manual. 8th ed. Switzerland: Springer; 2017. 819–31.
Eagle RC Jr. High-risk features and tumor differentiation in retinoblastoma: a retrospective histopathologic study. Arch Pathol Lab Med. 2009;133:1203–9.
pubmed: 19653710
Madhavan J, Ganesh A, Roy J, Biswas J, Kumaramanickavel G. The relationship between tumor cell differentiation and age at diagnosis in retinoblastoma. J Pediatr Ophthalmol Strabismus. 2008;45:22–5.
doi: 10.3928/01913913-20080101-16
Albon J, Karwatowski WS, Avery N, Easty DL, Duance VC. Changes in the collagenous matrix of the aging human lamina cribrosa. Br J Ophthalmol. 1995;79:368–75.
doi: 10.1136/bjo.79.4.368
Albon J, Purslow PP, Karwatowski WS, Easty DL. Age related compliance of the lamina cribrosa in human eyes. Br J Ophthalmol. 2000;84:318–23.
doi: 10.1136/bjo.84.3.318
Abramson DH, Gombos DS. The topography of bilateral retinoblastoma lesions. Retina. 1996;16:232–9.
doi: 10.1097/00006982-199616030-00009
Rada JA, Achen VR, Penugonda S, Schmidt RW, Mount BA. Proteoglycan composition in the human sclera during growth and aging. Invest Ophthalmol Vis Sci. 2000;41:1639–48.
pubmed: 10845580
Crosby MB, Hubbard GB, Gallie BL, Grossniklaus HE. Anterior diffuse retinoblastoma: mutational analysis and immunofluorescence staining. Arch Pathol Lab Med. 2009;133:1215–8.
pubmed: 19653712
pmcid: 2810483
Honavar SG, Singh AD, Shields CL, Meadows AT, Demirci H, Cater J, et al. Postenucleation adjuvant therapy in high-risk retinoblastoma. Arch Ophthalmol. 2002;120:923–31.
doi: 10.1001/archopht.120.7.923
Magramm I, Abramson DH, Ellsworth RM. Optic nerve involvement in retinoblastoma. Ophthalmology. 1989;96:217–22.
doi: 10.1016/S0161-6420(89)32910-1
Shields CL, Shields JA, Baez K, Cater JR, De Potter P. Optic nerve invasion of retinoblastoma. Metastatic potential and clinical risk factors. Cancer. 1994;73:692–8.
doi: 10.1002/1097-0142(19940201)73:3<692::AID-CNCR2820730331>3.0.CO;2-8
Kaliki S, Tahiliani P, Mishra DK, Srinivasan V, Ali MH, Reddy VA. Optic nerve infiltration by retinoblastoma: predictive clinical features and outcome. Retina. 2016;36:1177–83.
doi: 10.1097/IAE.0000000000000861